Catalyst Funds Management Pty LTD Denali Therapeutics Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 2,000 shares of DNLI stock, worth $56,900. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,000Holding current value
$56,900% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
226Shares Held
119MCall Options Held
44.5KPut Options Held
29.7K-
Baillie Gifford & CO13.3MShares$380 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$375 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$318 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$305 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$225 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.82B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...